Which fractionation of radiotherapy is best for limited-stage small-cell lung cancer?
Mené sur 547 patients atteints d'un cancer du poumon à petites cellules de stade limité (durée médiane de suivi : 45 mois), cet essai de phase III évalue, dans le cadre d'une chimioradiothérapie concomitante et du point de vue de la survie globale, la supériorité d'une radiothérapie ne comportant qu'une seule fraction quotidienne de rayonnements ionisants par rapport à une radiothérapie basée sur l'administration quotidienne de deux fractions
The role of radiotherapy in the treatment of small-cell lung cancer has been established through a series of clinical trials and meta-analyses during the past 20 years, which showed that local radiotherapy in addition to chemotherapy and whole-brain radiotherapy can improve patient prognosis. Moreover, use of radiotherapy with concurrent chemotherapy in the early stages of disease has been shown to further improve treatment outcomes. Results from the Intergroup 0096 trial4 showed that a radiotherapy dose of 45 Gy given twice daily led to improved prognosis when compared with once-daily fractionation regimens employing the same total radiotherapy dose.
The Lancet Oncology , commentaire, 2016